Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Saved in:
| Title: | Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. |
|---|---|
| Authors: | Schmidt J; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Chiffelle J; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Perez MAS; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland., Magnin M; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Bobisse S; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Arnaud M; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Genolet R; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Cesbron J; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Barras D; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Navarro Rodrigo B; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Benedetti F; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Michel A; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Queiroz L; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Baumgaertner P; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Guillaume P; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Hebeisen M; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland., Michielin O; Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Nguyen-Ngoc T; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland., Huber F; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Irving M; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland., Tissot-Renaud S; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Stevenson BJ; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland., Rusakiewicz S; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Dangaj Laniti D; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Bassani-Sternberg M; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Rufer N; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland., Gfeller D; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland., Kandalaft LE; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Speiser DE; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland., Zoete V; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland., Coukos G; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.; Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Harari A; Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland. Alexandre.Harari@chuv.ch.; Center for Cell Therapy, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland. Alexandre.Harari@chuv.ch. |
| Source: | Nature communications [Nat Commun] 2023 Jun 06; Vol. 14 (1), pp. 3188. Date of Electronic Publication: 2023 Jun 06. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-023-38946-z |
